Partnering

Current Partnering Opportunities

Biosurgery

EvitarTM (TTX-333) - Prevention of Tissue Fibrosis Formation following abdominal/pelvic surgery (Phase 2B/3):

  • Markets available: US, EU, & ROW, including Japan, China, S. Korea, ASEAN, Australia, India, MENA, CIS and LATAM for EvitarTM
  • The first drug shown in clinical trials to prevent tissue fibrosis formation following laparoscopic surgery. 
  • Partnership sought: R&D Collaboration with Option to License at NDA/MAA Approval

 

Endometriosis

TTX-334Dx-Non-invasive blood test for diagnosing endometriosis (entering Phase 2 trials)

  • Collaboration with EndoDiag (Paris, France)
  • Temple/EndoDiag will conduct clinical work and regulatory filings
  • Partnership sought: R&D Collaboration with option to license at approval (510K-CE-IVD)

TTX-334e-Drug candidate with novel MoA-non-hormonal therapy for Endometriosis

  • Temple will conduct preclinical and clinical work in conjunction with partner
  • Worldwide markets available
  • Partnership sought: R&D Collaboration with option to license at NDA/MAA approval

 

Oncology

TTX-335o-Novel targeted therapy for recurrent, sensitive and platinum resistant ovarian cancers (Preclinical)

  • Worldwide markets available
  • Data generated for recurrent, sensitive and platinum resistant ovarian cancer cells
  • Won prestigious EU Eurostars Grant in 2019 ($3M)
  • Data available in other cancers which can also be developed in conjunction with partner
  • Partnership sought: Option to license at IND or Phase 1 (build to buy)

 

Our medical advisors, collaborators and researchers work at the following organizations.

  • Brigham and Women's Hospital
  • Harvard Medical
  • Maastricht U
  • Cleveland Clinic
  • Oldenburg
  • Sahlgrenska Cancer Research Center
  • Guys St. Thomas
  • ukbb
  • Xenopat
  • usask
  • Insphero
  • dsm
  • evonik
  • Basel
  • Radboud UMC

MeEt Us

View our upcoming events

View All Events